752222-79-0

Basic information

• Product Name: 2,4(1H,3H)-Pyrimidinedione,6-amino-1-ethyl-5-nitroso-3-propyl-(9CI)
• Synonyms: 2,4(1H,3H)-Pyrimidinedione,6-amino-1-ethyl-5-nitroso-3-propyl-(9CI)
• CAS NO: 752222-79-0
• Molecular Formula: C9H14N4O3
• Molecular Weight: 226.23246
• Product Categories: ETHYL
• Mol File: 752222-79-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4(1H,3H)-Pyrimidinedione,6-amino-1-ethyl-5-nitroso-3-propyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4(1H,3H)-Pyrimidinedione,6-amino-1-ethyl-5-nitroso-3-propyl-(9CI)(752222-79-0)
• EPA Substance Registry System: 2,4(1H,3H)-Pyrimidinedione,6-amino-1-ethyl-5-nitroso-3-propyl-(9CI)(752222-79-0)

Safety Data

• Hazardous Substances Data: 752222-79-0(Hazardous Substances Data)

Upstream product

• 752222-78-9 N'-(3-ethyl-1,2,3,6-tetrahydro-2,6-dioxopyrimidin-4-yl)-N,N-dimethylformamidine 
• 41862-09-3 1-ethyl-6-aminouracil 
• 879328-64-0 6-[1-aza-2-(dimethylamino)vinyl]-1-ethyl-3-propyl-1,3-dihydropyrimidine-2,4-dione 
• 63981-31-7 6-amino-1-ethyl-3-propylpyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 752222-81-4 5,6-diamino-1-ethyl-3-propylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension

This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A2B receptor antagonist to the patient.

METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS

The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.